Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe


Autoři: Saziso Nyathi aff001;  Riitta A. Dlodlo aff002;  Srinath Satyanarayana aff002;  Kudakwashe C. Takarinda aff002;  Hannock Tweya aff005;  Sithokozile Hove aff001;  Ronnie Matambo aff003;  Winnie Mandewo aff007;  Khulamuzi Nyathi aff001;  Edwin Sibanda aff001;  Anthony D. Harries aff002
Působiště autorů: Health Services Department, City of Bulawayo, Bulawayo, Zimbabwe aff001;  International Union Against Tuberculosis and Lung Disease (The Union), Paris, France aff002;  International Union Against Tuberculosis and Lung Disease (The Union), Harare, Zimbabwe aff003;  AIDS and TB Directorate, Ministry of Health and Child Care, Harare, Zimbabwe aff004;  Light House Trust, Lilongwe, Malawi aff005;  Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, England, United Kingdom aff006;  Elizabeth Glaser Peadiatric AIDS Foundation, Harare, Zimbabwe aff007
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223076

Souhrn

Setting

Four primary health care clinics providing tuberculosis (TB) and Human Immunodeficiency Virus care services in Bulawayo, Zimbabwe.

Objectives

To assess isoniazid preventive therapy (IPT) initiation and completion, factors associated with IPT uptake and incidence of TB, and TB and antiretroviral treatment (ART) outcomes among people living with HIV (PLHIV).

Design

This was a cohort study using routine data in the records for PLHIV initiated on ART from October 2013 to March 2014 with 31 December 2017 as the end of the follow-up period.

Results

A total of 408 PLHIV were eligible for IPT, 214 (52%) were initiated on IPT and 201 (94%) completed IPT. No person in the IPT-initiated group developed Tuberculosis (TB). Six persons with TB were reported among the non-IPT-initiated group leading to an incidence of 9 cases/1,000 person-years of follow-up. About 70% of those who developed and were treated for TB had a successful TB treatment outcome. The survival on ART at four years of follow-up was 88% among the IPT-initiated PLHIV that was significantly higher than the 75% survival in the group not- initiated on IPT.

Conclusion

The study revealed low IPT initiation among eligible PLHIV who, if started on IPT, completed the six month regimen. TB was reported only among the PLHIV not-initiated on IPT and the four year ART survival was higher in the IPT-initiated group than in the non-initiated group. These findings reinforce the need to strengthen IPT uptake among PLHIV in Bulawayo.

Klíčová slova:

Age groups – Antiretroviral therapy – HIV – HIV prevention – Isoniazid – Tuberculosis – Tuberculosis diagnosis and management – Zimbabwe


Zdroje

1. UNAIDS. Global HIV and AIDS statistics—2018 fact sheet. Genava, Switzerland; 2018.

2. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection. N Engl J Med. 1989;320: 545–550. doi: 10.1056/NEJM198903023200901 2915665

3. World Health Organisation. Global TB Report. Geneva, Switzerland; 2017.

4. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2017. 2017. UNAIDS/JC2910E

5. Harries AD, Schwoebel V, Monedero-Recuero I, Aung TK, Chadha S, Chiang C-Y, et al. Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries. Int J Tuberc lung Dis. 2019;23: 241–251. doi: 10.5588/ijtld.18.0207 30808459

6. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis. Nunn A, editor. PLoS Med. 2012;9: e1001270. doi: 10.1371/journal.pmed.1001270 22911011

7. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373: 808–822. doi: 10.1056/NEJMoa1507198 26193126

8. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet (London, England). 2014;384: 682–90. doi: 10.1016/S0140-6736(14)60162-8 24835842

9. Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS. 2010;24 Suppl 5: S5–13. doi: 10.1097/01.aids.0000391010.02774.6f 21079429

10. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Heal. 2017;5: e1080–e1089. doi: 10.1016/S2214-109X(17)30372-8

11. World Health Organisation. WHO Guidelines on Intensified Tuberculosis Case Finding for People Living With HIV in Resource Constrained Settings. Geneva, Switzerland; 2012.

12. Health Services Department-City of Bulawayo. 2017 Annual Report. Bulawayo; 2017.

13. Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16: 840. doi: 10.1186/s12889-016-3525-8 27543096

14. Zimbabwe National Statistical Agency. Zimbabwe National Population Census Report 2012. Harare; 2014.

15. Takarinda KC, Choto RC, Harries AD, Mutasa-Apollo T, Chakanyuka-Musanhu C. Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. Public Heal action. 2017;7: 55–60. doi: 10.5588/pha.16.0102 28775944

16. World Health Organisation. Global Health TB Report. Geneva, Switzerland; 2018.

17. Ministry of Health and Child Care. National TB and Leprosy Guidelines, Zimbabwe. 2017.

18. World Health Organisation. Adverse Events associated with the use of Isoniazid Preventive Therapy among people living with HIV. 2015.

19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int J Surg. 2014;12: 1495–1499. doi: 10.1016/j.ijsu.2014.07.013 25046131

20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335: 806–8. doi: 10.1136/bmj.39335.541782.AD 17947786

21. Lewis JJ, Fielding KL, Grant AD, Chihota VN, Popane F, Luttig M, et al. Eligibility for Isoniazid Preventive Therapy in South African Gold Mines. Polis MA, editor. PLoS One. 2013;8: e81376. doi: 10.1371/journal.pone.0081376 24244741

22. Thindwa D, MacPherson P, Choko AT, Khundi M, Sambakunsi R, Ngwira LG, et al. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi. Int J Tuberc Lung Dis. 2018;22: 273–279. doi: 10.5588/ijtld.17.0370 29471904

23. National Medicines and Therapeutics Policy Advisory Committee, And, Ministry of Health and Child Care. Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe. Harare; 2016.

24. Makoni A, Chemhuru M, Tshimanga M, Gombe NT, Mungati M, Bangure D. Evaluation of the isoniazid preventive therapy (IPT) program in Shurugwi District, Midlands Province, Zimbabwe, January 2013 to August 2014. BMC Res Notes. 2015;8: 476. doi: 10.1186/s13104-015-1451-y 26408193

25. Thindwa D, MacPherson P, Choko AT, Khundi M, Sambakunsi R, Ngwira LG, et al. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi. Int J Tuberc Lung Dis. 2018;

26. Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Shenoi S V. “It’s about my life”: facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care. 2017;29: 936–942. doi: 10.1080/09540121.2017.1283390

27. Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Heal December 2016. Geneva, Switzerland; 2016;16: 840. doi: 10.1186/s12889-016-3525-8 27543096

28. Maharaj B, Gengiah TN, Yende-Zuma N, Gengiah S, Naidoo A, Naidoo K. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis. 2017;21: 537–543. doi: 10.5588/ijtld.16.0775 28399969

29. Adams L V, Talbot EA, Odato K, Blunt H, Steingart KR. Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. BMC Infect Dis. 2014;14: 281. doi: 10.1186/1471-2334-14-281 24886159

30. Takarinda KC, Harries AD, Mutasa-Apollo T, Sandy C, Murimwa T, Mugurungi O. ART uptake, its timing and relation to anti-tuberculosis treatment outcomes among HIV-infected TB patients. Public Heal Action. 2012;2: 50–55. doi: 10.5588/pha.12.0011 26392951

31. Weldegebreal F, Mitiku H, Teklemariam Z. Treatment outcome of tuberculosis among Human Immunodeficiency Virus positive patients in Eastern Ethiopia: a retrospective study. Pan Afr Med J. 2018;30. doi: 10.11604/pamj.2018.30.32.12554 30167059

32. Lai J, Dememew Z, Jerene D, Abashawl A, Feleke B, Teklu AM, et al. Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2019;23: 371–377. doi: 10.5588/ijtld.18.0378 30871669


Článek vyšel v časopise

PLOS One


2019 Číslo 10

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se